Doximity, Inc. (DOCS)
NYSE: DOCS · Real-Time Price · USD
26.65
+0.33 (1.25%)
Sep 3, 2026, 11:32 AM EDT - Market open
Doximity Revenue
Doximity had revenue of $156.62M in the quarter ending June 30, 2026, with 7.34% growth. This brings the company's revenue in the last twelve months to $655.57M, up 11.18% year-over-year. In the fiscal year ending March 31, 2026, Doximity had annual revenue of $644.86M with 13.05% growth.
Revenue (ttm)
$655.57M
Revenue Growth
+11.18%
P/S Ratio
7.37
Revenue / Employee
$744,964
Employees
880
Market Cap
4.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 644.86M | 74.46M | 13.05% |
| Mar 31, 2025 | 570.40M | 94.98M | 19.98% |
| Mar 31, 2024 | 475.42M | 56.37M | 13.45% |
| Mar 31, 2023 | 419.05M | 75.50M | 21.98% |
| Mar 31, 2022 | 343.55M | 136.65M | 66.05% |
| Mar 31, 2021 | 206.90M | 90.51M | 77.76% |
| Mar 31, 2020 | 116.39M | 30.69M | 35.82% |
| Mar 31, 2019 | 85.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 14.37B |
| Privia Health Group | 2.36B |
| Tempus AI | 1.43B |
| HealthEquity | 1.36B |
| Omnicell | 1.25B |
| Waystar Holding | 1.21B |
| Hinge Health | 720.06M |
| 10x Genomics | 616.91M |
DOCS News
- 6 days ago - Doximity Transcript: AGM 2026 - Transcripts
- 9 days ago - Overworked Doctors Bet on AI to Boost Their Pay - Business Wire
- 17 days ago - Doximity price target raised to $24 from $19 at Truist - TheFly
- 24 days ago - Doximity downgraded to Underweight from Equal Weight at Wells Fargo - TheFly
- 26 days ago - Doximity stock is reversing post-earnings rally: why that shouldn't surprise you - Invezz
- 26 days ago - Doximity rises 36.2% - TheFly
- 26 days ago - Here's Why Doximity Stock Is Flying Today - Investopedia
- 27 days ago - Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last? - Market Watch